On January 31st, at the BSMO 2025 Congress, Dr. Nuytemans (AZ Groeninge) unveiled the insights from a Belgian multi-center real-world study in breast cancer patients.
On January 31st, at the Belgian Society of Molecular Oncology, Dr. Nuytemans (AZ Groeninge) unveiled the insights from a Belgian multi-center real-world study in breast cancer patients. This study delved into the distribution of breast cancer molecular subtypes and their clinical characteristics at both diagnosis and after relapse or progression. By harnessing routinely collected hospital data and cutting-edge artificial intelligence technologies within a federated model, this study may lead to a better understanding of the Belgian breast cancer population during their disease course.
Authors: Nuytemans L. (AZ Groeninge), Teuwen LA (UZA), Germonprez F (AZMM), Masuy I (LynxCare), Iven J (AstraZeneca Belux), Muylle M (AstraZeneca Belux), Verbiest A (UZA)
Read more on BSMO.be – The Belgian Society of Medical Oncology (BSMO)